Literature DB >> 8465888

Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression.

M D De Bellis1, P W Gold, T D Geracioti, S J Listwak, M A Kling.   

Abstract

The authors measured CSF concentrations of corticotropin-releasing hormone (CRH) and arginine vasopressin in nine depressed patients before and after fluoxetine treatment. They found significant decreases in CSF CRH, CSF arginine vasopressin, and Hamilton depression ratings. Thus, the therapeutic effect of this serotonin-uptake inhibitor may be related to diminution of these arousal-promoting neuropeptides.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8465888     DOI： 10.1176/ajp.150.4.656

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  55 in total

1.  Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates.

Authors:  K E Habib; K P Weld; K C Rice; J Pushkas; M Champoux; S Listwak; E L Webster; A J Atkinson; J Schulkin; C Contoreggi; G P Chrousos; S M McCann; S J Suomi; J D Higley; P W Gold
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 2.  Evidence for the role of corticotropin-releasing factor in major depressive disorder.

Authors:  R Parrish Waters; Marion Rivalan; D A Bangasser; J M Deussing; M Ising; S K Wood; F Holsboer; Cliff H Summers
Journal:  Neurosci Biobehav Rev       Date:  2015-08-10       Impact factor: 8.989

3.  Lamotrigine inhibits basal and Na+-stimulated, but not Ca2+-stimulated, release of corticotropin-releasing hormone from the rat hypothalamus.

Authors:  Giuseppe Tringali; Jean Michel Aubry; Pierluigi Navarra; Giacomo Pozzoli
Journal:  Psychopharmacology (Berl)       Date:  2006-09-01       Impact factor: 4.530

4.  Interaction of stress, corticotropin-releasing factor, arginine vasopressin and behaviour.

Authors:  Eléonore Beurel; Charles B Nemeroff
Journal:  Curr Top Behav Neurosci       Date:  2014

Review 5.  Neurobiology of resilience in depression: immune and vascular insights from human and animal studies.

Authors:  Katarzyna A Dudek; Laurence Dion-Albert; Fernanda Neutzling Kaufmann; Ellen Tuck; Manon Lebel; Caroline Menard
Journal:  Eur J Neurosci       Date:  2019-09-13       Impact factor: 3.386

6.  Sexual differentiation of vasopressin innervation of the brain: cell death versus phenotypic differentiation.

Authors:  Geert J de Vries; Michelle Jardon; Mohammed Reza; Greta J Rosen; Eleanor Immerman; Nancy G Forger
Journal:  Endocrinology       Date:  2008-05-22       Impact factor: 4.736

7.  Two-week treatment with the selective serotonin reuptake inhibitor citalopram reduces contextual anxiety but not cued fear in healthy volunteers: a fear-potentiated startle study.

Authors:  Christian Grillon; Chanen Chavis; Matthew F Covington; Daniel S Pine
Journal:  Neuropsychopharmacology       Date:  2008-09-17       Impact factor: 7.853

Review 8.  The CRF system, stress, depression and anxiety-insights from human genetic studies.

Authors:  E B Binder; C B Nemeroff
Journal:  Mol Psychiatry       Date:  2009-12-15       Impact factor: 15.992

Review 9.  Update on stress and depression: the role of the hypothalamic-pituitary-adrenal (HPA) axis.

Authors:  Andrea de Abreu Feijó de Mello; Marcelo Feijó de Mello; Linda L Carpenter; Lawrence H Price
Journal:  Braz J Psychiatry       Date:  2004-01-15       Impact factor: 2.697

10.  Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders.

Authors:  J D Coplan; M W Andrews; L A Rosenblum; M J Owens; S Friedman; J M Gorman; C B Nemeroff
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.